CL2020002199A1 - Compuesto de anillo de metillactama y uso farmacéutico del mismo. - Google Patents

Compuesto de anillo de metillactama y uso farmacéutico del mismo.

Info

Publication number
CL2020002199A1
CL2020002199A1 CL2020002199A CL2020002199A CL2020002199A1 CL 2020002199 A1 CL2020002199 A1 CL 2020002199A1 CL 2020002199 A CL2020002199 A CL 2020002199A CL 2020002199 A CL2020002199 A CL 2020002199A CL 2020002199 A1 CL2020002199 A1 CL 2020002199A1
Authority
CL
Chile
Prior art keywords
methylactam
pharmaceutical use
ring compound
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
CL2020002199A
Other languages
English (en)
Spanish (es)
Inventor
Tomoya Miura
Yoshinori Tamatani
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of CL2020002199A1 publication Critical patent/CL2020002199A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CL2020002199A 2018-03-01 2020-08-26 Compuesto de anillo de metillactama y uso farmacéutico del mismo. CL2020002199A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2018036307 2018-03-01

Publications (1)

Publication Number Publication Date
CL2020002199A1 true CL2020002199A1 (es) 2020-12-18

Family

ID=67806229

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002199A CL2020002199A1 (es) 2018-03-01 2020-08-26 Compuesto de anillo de metillactama y uso farmacéutico del mismo.

Country Status (21)

Country Link
US (3) US11014910B2 (enExample)
EP (1) EP3760624A4 (enExample)
JP (3) JP7206132B2 (enExample)
KR (1) KR102795351B1 (enExample)
CN (1) CN111757877B (enExample)
AR (1) AR114418A1 (enExample)
AU (1) AU2019227770B2 (enExample)
BR (1) BR112020016788A2 (enExample)
CA (1) CA3087859A1 (enExample)
CL (1) CL2020002199A1 (enExample)
IL (1) IL276311B2 (enExample)
MA (1) MA52427A (enExample)
MX (1) MX2020009070A (enExample)
MY (1) MY205197A (enExample)
PE (1) PE20210123A1 (enExample)
PH (1) PH12020551340A1 (enExample)
SA (1) SA520420037B1 (enExample)
SG (1) SG11202007120UA (enExample)
TW (1) TWI805699B (enExample)
WO (1) WO2019168096A1 (enExample)
ZA (1) ZA202004600B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI805699B (zh) * 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
SG11202009179TA (en) 2018-04-04 2020-10-29 Japan Tobacco Inc Pyrazole compounds substituted with heteroaryl and pharmaceutical use thereof
CN114585387B (zh) * 2019-09-04 2024-10-29 日本烟草产业株式会社 利用联用药物的糖尿病的治疗或预防方法
KR20220156574A (ko) 2020-03-19 2022-11-25 니뽄 다바코 산교 가부시키가이샤 만성 심부전의 치료 또는 예방 방법

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657282A (en) * 1969-01-23 1972-04-18 Merck & Co Inc Carboxyepoxyethyl-1-phosphonic acid and derivatives
FR2665898B1 (fr) 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
JPH04247081A (ja) 1991-02-01 1992-09-03 Takeda Chem Ind Ltd ５員複素環酸アミド類
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
WO2004069824A1 (ja) 2003-02-07 2004-08-19 Daiichi Pharmaceutical Co., Ltd. ピラゾール誘導体
AU2004200420A1 (en) 2003-03-11 2004-09-30 Astellas Pharma Inc. Inhibitor of cyclooxygenase
JP2006182648A (ja) 2003-04-08 2006-07-13 Dai Ichi Seiyaku Co Ltd ７員複素環誘導体
WO2004110351A2 (en) 2003-05-14 2004-12-23 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis c virus
TW200526588A (en) 2003-11-17 2005-08-16 Smithkline Beecham Corp Chemical compounds
TW200526641A (en) 2003-12-26 2005-08-16 Daiichi Seiyaku Co Amidopyrazole derivatives
CA2572745A1 (en) 2004-07-07 2006-02-16 Teresa Beeson Pyrazole amide derivatives, compositions containing such compounds and methods of use
KR20070089151A (ko) 2004-11-16 2007-08-30 지더블유 파마 리미티드 카나비노이드의 새로운 용도
JP2008007405A (ja) 2004-12-07 2008-01-17 Takeda Chem Ind Ltd カルボキサミド誘導体
ZA200800142B (en) * 2005-06-08 2009-05-27 Japan Tobacco Inc Heterocyclic compound
JP4137956B2 (ja) * 2005-06-08 2008-08-20 日本たばこ産業株式会社 複素環化合物
EP1889842A4 (en) 2005-06-08 2009-07-29 Japan Tobacco Inc HETEROCYCLIC CONNECTION
WO2007034279A2 (en) * 2005-09-19 2007-03-29 Pfizer Products Inc. C3a antagonists and pharmaceutical compositions thereof
WO2007098826A2 (en) 2006-01-18 2007-09-07 Siena Biotech S.P.A. Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof
WO2007125048A1 (en) 2006-04-27 2007-11-08 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising cbx cannabinoid receptor modulators and potassium channel modulators
US20080027014A1 (en) 2006-07-28 2008-01-31 Tanabe Seiyaku Co., Ltd. Novel SGLT inhibitors
CA2670418A1 (en) 2006-11-24 2008-05-29 Ac Immune Sa N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimers's
WO2008061796A2 (en) 2006-11-24 2008-05-29 Ac Immune Sa Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
CL2008000119A1 (es) 2007-01-16 2008-05-16 Wyeth Corp Compuestos derivados de pirazol, antagonistas del receptor nicotinico de acetilcolina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como demencia senil, alzheimer y esquizofrenia.
ES2466672T3 (es) 2007-04-02 2014-06-10 Theracos, Inc. Derivados de glicósido bencílico y métodos de uso
US20090181952A1 (en) 2008-01-14 2009-07-16 Wyeth Compounds useful as alpha7 nicotinic acetylcholine receptor agonists
MX2011000628A (es) 2008-07-15 2011-02-25 Novartis Ag Derivados de heteroarilo como inhibidores de dgat1.
CN110269856A (zh) 2010-03-30 2019-09-24 维颂公司 多取代芳族化合物作为凝血酶的抑制剂
AR087701A1 (es) 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
TWI805699B (zh) * 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
SG11202009179TA (en) 2018-04-04 2020-10-29 Japan Tobacco Inc Pyrazole compounds substituted with heteroaryl and pharmaceutical use thereof

Also Published As

Publication number Publication date
TWI805699B (zh) 2023-06-21
IL276311A (en) 2020-09-30
PE20210123A1 (es) 2021-01-19
KR20200128033A (ko) 2020-11-11
JP7206132B2 (ja) 2023-01-17
WO2019168096A1 (ja) 2019-09-06
AU2019227770B2 (en) 2023-10-05
MX2020009070A (es) 2020-10-08
US20190352284A1 (en) 2019-11-21
IL276311B1 (en) 2023-06-01
PH12020551340A1 (en) 2021-05-31
JP2019151627A (ja) 2019-09-12
JP2023026566A (ja) 2023-02-24
MY205197A (en) 2024-10-07
SA520420037B1 (ar) 2024-07-28
JP2025026615A (ja) 2025-02-21
TW202000660A (zh) 2020-01-01
BR112020016788A2 (pt) 2021-01-12
CN111757877A (zh) 2020-10-09
US20220064148A1 (en) 2022-03-03
AR114418A1 (es) 2020-09-02
SG11202007120UA (en) 2020-08-28
US11014910B2 (en) 2021-05-25
ZA202004600B (en) 2022-03-30
KR102795351B1 (ko) 2025-04-16
RU2020131756A (ru) 2022-03-28
MA52427A (fr) 2021-01-06
US20240174646A1 (en) 2024-05-30
EP3760624A1 (en) 2021-01-06
EP3760624A4 (en) 2021-11-03
IL276311B2 (en) 2023-10-01
CN111757877B (zh) 2023-10-27
CA3087859A1 (en) 2019-09-06
AU2019227770A1 (en) 2020-07-09

Similar Documents

Publication Publication Date Title
DOP2022000124A (es) Derivados de pirazolilo útiles como agentes anticancerígenos
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
CL2020003257A1 (es) Compuestos antagonistas de pcsk9.
CL2020002199A1 (es) Compuesto de anillo de metillactama y uso farmacéutico del mismo.
MX2018005708A (es) Compuesto de 7-(tiazol-5-il)pirrolopirimidina como agonista de tlr7.
MX2016013908A (es) Novedoso compuesto de 1,2,4-triazina disustituida.
UY37645A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
MX2022009352A (es) Sal de hemisulfato de nucleotido para el tratamiento del virus de hepatitis c.
MX390747B (es) Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico.
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
UY37646A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
UY37742A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
AR103680A1 (es) Inhibidores selectivos de bace1
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
CR20180496A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112015030399B8 (pt) Derivados heterocíclicos, uso dos referidos derivados e composição farmacêutica para a prevenção ou tratamento de doenças associadas com a ativação da proteína stat3
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
CO2018001700A2 (es) Derivados de n-[1h-bencimidazol-2-il] metil-pirazin-2-il-carboxamida, composiciones y procedimientos de preparación de los mismos
UY36124A (es) Derivados de carboxamida
MX2020003732A (es) Derivado de anillo fusionado como inhibidor del receptor a2a.
CL2020002188A1 (es) Compuestos de dihidropirimidinona o dihidrotriazinona fusionados con anillos saturados y su uso farmacéutico.
BR112021011325A2 (pt) Derivados de rapamicina
MX2021009971A (es) Compuesto heterociclico, composicion farmaceutica que lo comprende, metodo para su preparacion, y uso de estos.
BR112022000155A2 (pt) Composição inibidora da micromolécula pi4kiiia, seu método de preparação, e uso da mesma
MX2018008153A (es) Derivados de c-glicósido que tienen anillos de fenilo condensado o sales farmacéuticamente aceptables de los mismos, metodo para prepararlos y composición farmacéutica que los contiene.